Facts & Figures

Selected key financial figures

In EUR mio. 2023 2022 2021
Revenues 9.18 11.28 11.63
Operating result (EBIT) -5.13 -4.91 -4.14
Loss for the year -6.79 -6.40 -5.89
Cash and cash equivalents per 31.12. 2.59 8.18 5.80
Balance sheet total per 31.12. 14.61 22.29 21.34
Net cash flow -5.59 2.37 -3.40
R&D expenses 7.03 6.91 7.50

Marinomed Corporate Presentation

Lucia Ziegler, MSc
Head of Investor & Public Relations
Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg, Austria
+43 2262 90300
office@marinomed.com